Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02206763 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

Interventions

DRUG: Momelotinib (MMB)
DRUG: Erlotinib

Sponsor

Sierra Oncology LLC - a GSK company